HERNDON, Va., Nov. 7, 2016 /PRNewswire/ -- Global technology company Nuix has appointed former Dun & Bradstreet executive Ethan Treese as its Chief Executive Officer—Americas. Treese's appointment will allow long-serving executive Dr. Jim Kent to focus on his role as Global Head of Security & Intelligence. "More than 60% of our revenue now comes from North America and our business in Central and South America is also growing; we absolutely needed a full-time CEO driving that business," said Eddie Sheehy, CEO of Nuix worldwide. "Ethan is a highly qualified business leader who understands and fits in well with the Nuix culture and I look forward to achieving great things in our American markets under his guidance." Before joining Nuix, Treese served in a variety of leadership and business development roles at Dun & Bradstreet. He has extensive experience growing key clients and industries including technology, telecommunications, retail, transportation, manufacturing, insurance, and the public sector. Treese takes over the CEO—Americas role from Kent, who remains the company's Global Head of Security & Intelligence. Kent will now be focused on growing the company's Security & Intelligence business worldwide and preparing to launch the Nuix Insight range of cybersecurity products in 2017. "We've been working for nearly three years on building the Nuix Insight products in parallel with making the Nuix Engine a massively scalable investigation platform," said Kent. "Those capabilities combined will revolutionize the way investigations are conducted because they'll make it possible to search and examine the context of digital evidence from petabytes of data. Our ability to extract intelligence is the key that has been missing in law enforcement and government investigations—and no other technology in the world can do that." Treese is also a Director of the BrightFocus Foundation, a nonprofit organization that supports research and provides public education to help eradicate brain and eye diseases including Alzheimer's disease, macular degeneration, and glaucoma.